GlassScriptPhysician profile
Jessica Burks
NPI 1083188080
$2,409.57
in general payments reported to CMS, 2019-2025
27 companies · $691 in 2025
The $691 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $678 · 2023: $647 · 2024: $394 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.30 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $313.94 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $289.68 | 2023-2025 | Ingrezza, Ongentys |
| Novo Nordisk INC | $263.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $235.59 | 2021-2025 | Rexulti, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $110.88 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.44 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $74.32 | 2023-2025 | Kisunla, Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $69.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $64.67 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $54.81 | 2021-2023 | Trintellix |
| Glaxosmithkline, LLC. | $47.08 | 2021 | |
| Lundbeck LLC | $41.54 | 2023-2024 | Rexulti |
| Sun Pharmaceutical Industries INC. | $41.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.61 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $35.47 | 2021 | |
| Astellas Pharma US INC | $32.13 | 2025 | Veozah |
| Exact Sciences Corporation | $30.34 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $28.10 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.23 | 2021 | |
| Indivior INC. | $16.78 | 2023 | Perseris |
| Bayer Healthcare Pharmaceuticals INC. | $13.56 | 2023 | |
| Pfizer INC. | $13.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.96 | 2023 | Eliquis |
| Eisai INC. | $12.04 | 2021 | |
| Genentech USA, INC. | $10.21 | 2021 | |
| Organon LLC | $7.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.